desvenlafaxine succinate sustained release — Competitive Intelligence Brief

desvenlafaxine succinate sustained release (desvenlafaxine succinate sustained release) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin-norepinephrine reuptake inhibitor (SNRI). Area: Psychiatry / Neurology.

marketed Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin transporter (SERT) and norepinephrine transporter (NET) Psychiatry / Neurology Small molecule

Target snapshot

desvenlafaxine succinate sustained release (desvenlafaxine succinate sustained release) — Pfizer. Desvenlafaxine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their synaptic availability.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
desvenlafaxine succinate sustained release TARGET	desvenlafaxine succinate sustained release	Pfizer	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT) and norepinephrine transporter (NET)
Pristiq	Desvenlafaxine Succinate	Pfizer	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin and norepinephrine reuptake	2008-01-01
Effexor	Venlafaxine Hydrochloride	Pfizer	marketed	Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)	Serotonin and norepinephrine reuptake transporters	1993-01-01
toludesvenlafaxine hydrochloride sustained-release tablets	toludesvenlafaxine hydrochloride sustained-release tablets	Shanghai Mental Health Center	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT) and norepinephrine transporter (NET)
venlafaxine (Effexor)	venlafaxine (Effexor)	National Institute of Mental Health (NIMH)	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT, weak)
VenlafaxineXR	VenlafaxineXR	National Institute of Mental Health (NIMH)	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT); Norepinephrine transporter (NET)
Venlafaxine IR and Venlafaxine XR	Venlafaxine IR and Venlafaxine XR	North Dakota State University	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT) and norepinephrine transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin-norepinephrine reuptake inhibitor (SNRI) class)

1. Pfizer · 3 drugs in this class
2. Wyeth is now a wholly owned subsidiary of Pfizer · 3 drugs in this class
3. National Institute of Mental Health (NIMH) · 2 drugs in this class
4. Zhejiang Huahai Pharmaceutical Co., Ltd. · 2 drugs in this class
5. Eli Lilly and Company · 2 drugs in this class
6. New York State Psychiatric Institute · 1 drug in this class
7. North Dakota State University · 1 drug in this class
8. Ministry of Health & Welfare, Korea · 1 drug in this class
9. Purdue Pharma, Canada · 1 drug in this class
10. Shanghai Mental Health Center · 1 drug in this class